ClinicalTrials.gg
CompletedNCT01191684Updated Oct 19, 2026

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

A Phase 1 interventional study of laboratory biomarker analysis and enzyme-linked immunosorbent assay in Recurrent Colon Cancer, Recurrent Gastric Cancer and Recurrent Pancreatic Cancer, sponsored by City of Hope Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Updated Oct 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Colonic Neoplasms by City of Hope Medical Center — 6 open to participants now, 9 under way, none of them phase 3. Colonic Neoplasms · City of Hope Medical Center.

Enrollment
16th of 24
12 · median 20
Started
2011
with 2 others
Phase 1
10 of 30
none open now
Registered
9th of 30
by date

Among the 30 studies in Colonic Neoplasms by City of Hope Medical Center, this one is the 16th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2011, is one of 10 in phase 1, and was the 9th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

6 of the 30 studies in Colonic Neoplasms by City of Hope Medical Center are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Colonic Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer.

Read the detailed description

PRIMARY OBJECTIVES:I. To establish whether 2 vaccine dose levels of modified vaccinia virus ankara vaccine expressing p53 (MVAp53) vaccines are safe and well tolerated in patients with p53 over-expressing solid tumor malignancy.

SECONDARY OBJECTIVES:I. To provide preliminary evidence of enhanced cellular and humoral immunity to p53.

OUTLINE:This is a phase I, dose-escalation trial of modified vaccinia virus ankara vaccine expressing p53 (MVAp53).Patients receive MVAp53 subcutaneously (SC) on days 0, 21, and 42 in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed up annually for 5 years.

03

Conditions studied

  • Recurrent Colon Cancer
  • Recurrent Gastric Cancer
  • Recurrent Pancreatic Cancer
  • Recurrent Rectal Cancer
  • Stage III Colon Cancer
  • Stage III Gastric Cancer
  • Stage III Pancreatic Cancer
  • Stage III Rectal Cancer
  • Stage IV Colon Cancer
  • Stage IV Gastric Cancer
  • Stage IV Pancreatic Cancer
  • Stage IV Rectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with unresectable and chemotherapy resistant primary or recurrent carcinoma of colorectal, gastric or pancreatic origin
  • There must be pathologic evidence for with a soft tissue component of tumor evident on CT scan imaging or physical examination
  • Patient must be able to give
  • There must be an anticipated survival of at least 3 months
  • Performance status of 80-100 ( performance status)
  • WBC count >= 3,000uL
  • count >= 100,000uL
  • and partial thromboplastin time of \<= 1.5 times the
  • Women of must have a negative pregnancy test; women and men of childbearing potential must agree to use adequate (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant during or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  • Patients with asymptomatic small volume bone disease not likely to require radiation therapy during the period of the vaccine trial will be eligible
  • level > 9g/dL
  • There must be evidence of p53 over expression by immunohistochemistry with > 10% of cells within the tumor strongly positive
  • Patients with colorectal cancer will need to have failed to respond to 5-FU based therapy with oxaliplatin, irinotecan as well as epidermal growth factor receptor (EGFR) directed therapies (if appropriate); patients with gastric cancer will need to have progressed on standard chemotherapy or chemoradiotherapy and Herceptin based therapy (if appropriate); patients with pancreatic cancer who have failed to respond to at least 1 chemotherapy regimen

Exclusion criteria

Exclusion Criteria:

  • Diagnosis which has been associated with immunodeficiency, including
  • Prior radiation to more than 50% of all nodal groups
  • Concurrent use of
  • History of another , other than nonmelanoma skin cancer in the past 2 years
  • Recent major surgery
  • Serious intercurrent illness
  • Temperature >= 101F within 3 days prior to the initial injection
  • Pregnancy or lactation
  • Clinically evident
  • disease
  • HIV seropositivity or refusal to hear the results of the HIV test
  • Receipt of organ grafts
  • History of severe environmental allergies
  • History of severe neurological, cardiovascular, renal, hepatic, endocrine, respiratory, or bone marrow dysfunction requiring frequent re-evaluation, and management by a physician
  • Patients with a history of congestive heart failure or coronary artery disease which has not been resolved by bypass or stent
  • History of myopericarditis
  • Known family history of Li-Fraumeni syndrome
  • Allergy to egg proteins
  • Chemotherapy or radiation within the 4 weeks preceding enrollment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment (vaccine therapy)

    Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.

    Other: laboratory biomarker analysis · Other: enzyme-linked immunosorbent assay · Other: flow cytometry · Other: immunoenzyme technique · Biological: modified vaccinia virus ankara vaccine expressing p53

Interventions

  • Otherlaboratory biomarker analysis

    Correlative studies

  • Otherenzyme-linked immunosorbent assay

    Correlative studies

    Also known as: ELISA

  • Otherflow cytometry

    Correlative studies

  • Otherimmunoenzyme technique

    Correlative studies

    Also known as: immunoenzyme techniques

  • BiologicalMVAp53 vaccineStudies of MVAp53 vaccineMVAp53 vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: MVA-p53 vaccine, MVAp53 vaccine

06

What researchers measure

Primary outcomes

  1. Safety and tolerance of modified vaccinia virus ankara vaccine expressing p53 assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicity scale

    Safety data for each administered dose will be summarized using descriptive numbers and 95% confidence intervals from the exact binomial distributions

    Time frame: Assessed up to 12 months

Secondary outcomes

  1. Immunogenicity

    Assessed using enzyme-linked immunosorbent assay (ELISA) for humoral response, lymphoproliferation for cluster of differentiation (CD)4+ T cell response, and intracytoplasmic cytokine assays, and interferon (IFN)-gamma and interleukin (IL)-4 by enzyme-linked immunosorbent spot (ELISPOT) for the assessment of cellular immune response. For each assay, the pre-vaccine values will be compared to the highest post-vaccine values. Immunogenicity changes and the maximum change will be quantified by mean, standard deviation, median, and range and tested by paired t-test at the 0.05 significance level.

    Time frame: Assesse up to 12 months

07

Study locations

1 site
  • City of Hope Medical Center
    Duarte, California 91010, United States
08

References and documents

Publications

  • Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res. 2014 Sep 1;20(17):4459-70. doi: 10.1158/1078-0432.CCR-13-3361. Epub 2014 Jul 1. PubMed 24987057 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Aug 2013, 19 months.

Of 65 non-industry phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 69. This study's 19 months is below that.

Counting every sponsor, half of 116 studies reached it within 49 months; a quarter within 32 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Oct 2011 → Dec 2011, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2010
First posted
Aug 31, 2010
StartActual
Dec 22, 2011was Oct 2011
Primary completionActual
Aug 19, 2013
CompletionActual
Aug 19, 2013
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2011→Dec 22, 2011 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Oct 2011→Dec 22, 2011 (now actual)
    + 3 other changes: index terms, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01191684
Responsible party
Sponsor
First posted
Aug 31, 2010
Start date
Dec 22, 2011
Primary completion
Aug 19, 2013
Completion
Aug 19, 2013
Last update
Oct 19, 2026

Study contacts

Vincent Chung, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVAp53 vaccine

Start the discussion